期刊文献+

Ki-67抗原与乳腺癌的相关性研究 被引量:5

Correlative Research of Ki-67 Antigen in Breast Cancer
原文传递
导出
摘要 目的探讨Ki-67抗原在乳腺癌组织中的表达,并评价其表达与乳腺癌生物学行为及判断乳腺癌预后的关系。方法检索近年来有关Ki-67与乳腺癌的相关性研究的文献并做综述。结果 Ki-67在乳腺癌组织中的表达水平显著高于癌旁组织及正常乳腺组织,且Ki-67表达阳性率与乳腺癌病理分级、临床分期呈正相关,而Ki-67表达与乳腺癌腋窝淋巴结转移的相关性研究结果不尽一致。结论 Ki-67抗原是与细胞增殖周期相关的细胞核抗原,其表达随细胞周期的变化而变化,是检测细胞增殖活性较为可靠的标志物,其可能成为判断肿瘤恶性程度及评估预后的重要指标;Ki-67表达水平的检测在乳腺肿瘤的早期诊断、指导新辅助化疗、评估预后等方面有重要意义。 Objective To explore the expression of Ki-67 antigen in the breast cancer tissues and to evaluate the relationship of the expression to biology behavior as well as prognosis of breast cancer. Method Literatures about relation between Ki-67 and breast cancer were reviewed. Results The expression of Ki-67 in the breast cancer tissue was obviously higher than that in the adjacent to cancer tissue or normal breast tissue. The Ki-67 positive expression rate was positively correlated with pathology classification and clinical stage of breast cancer, the correlation was not consistent about the expression of Ki-67 and axillary lymph node metastasis of breast cancer. Conclusions Ki-67 is a cell proliferation nuclear antigen related to cell cycle , and its expression changes along with the change of cell cycle, it has been employed as a reliable marker of cell proliferation. The expression of Ki-67 has an important significance in early diagnosis and guiding of neoadjuvant chemotherapy as well as prognosis of breast cancer.
出处 《中国普外基础与临床杂志》 CAS 2014年第5期650-653,共4页 Chinese Journal of Bases and Clinics In General Surgery
关键词 KI-67抗原 乳腺癌 细胞增殖 临床应用 Ki-67antigen Breast cancer Cell proliferation Clinical application
  • 相关文献

参考文献41

  • 1Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90. 被引量:1
  • 2杨桦,王思愚,区伟,孙海波,方勤.华南地区年轻乳腺癌患者的临床特征及预后因素分析[J].癌症,2009,28(12):1310-1316. 被引量:19
  • 3Fredholm H,Eaker S,Frisell J,et al.Breast cancer in young women:Poor survival despite intensive treatment[J].PLoS One,November 11,2009.doi:10.1371/journal.pone.0007695. 被引量:1
  • 4马志君,吉洁.Ki67与肿瘤关系的研究进展[J].中国医疗前沿,2012,7(7):15-17. 被引量:19
  • 5邓秀娟,吴海根.PTEN、Ki67在卵巢恶性肿瘤组织中的研究进展[J].现代肿瘤医学,2012,20(10):2182-2184. 被引量:6
  • 6Goldhirsch A,Ingle JN,Gelber RD,et al.Thresholds for thera-pies:highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009[J].Ann Oncol,2009,20(8):1319-1329. 被引量:1
  • 7Oakman C,Bessi S,Zafarana E,et al.Recent advances in systemic therapy.New diagnostics and biological predictors of outcome in early breast cancer[J].Breast Cancer Res,2009,11(2):205. 被引量:1
  • 8Gerdes J,Schwab U,Lemke H,et al.Production of a mouse mono-clonal antibody reactive with a human nuclear antigen associated with cell proliferation[J].Int J Cancer,1983,31(1):13-20. 被引量:1
  • 9Schlüter C,Duchrow M,Wohlenberg C,et al.The cell prolifer-ation-associated antigen of antibody Ki-67:a very large,ubiqui-tous nuclear protein with numerous repeated elements,representinga new kind of cell cycle-maintaining proteins[J].J Cell Biol,1993,123(3):513-522. 被引量:1
  • 10MacCallum DE,Hall PA.The location of pKi67 in the outer dense fibrillary compartment of the nucleolus points to a role in ribosome biogenesis during the cell division cycle[J].J Pathol,2000,190(5):537-544. 被引量:1

二级参考文献257

共引文献228

同被引文献42

  • 1Zheng, Yao,Wang, Lin,Zhang, Jian-Ping,Yang, Jing-Yan,Zhao, Zhu-Mei,Zhang, Xiao-Ying.Expression of p53,c-erbB-2 and Ki67 in intestinal metaplasia and gastric carcinoma[J].World Journal of Gastroenterology,2010,16(3):339-344. 被引量:34
  • 2杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1504
  • 3Goldhirsch A,Wood WC,Coates AS,et al.Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.Ann Oncol,2011,22(8): 1736-1747. 被引量:1
  • 4Berger JM,Gamblin SJ,Harrison SC,et al.Structure and mechanismof DNA topoismerase Ⅱ .Nature,1996,379(6562): 225-232. 被引量:1
  • 5Harris LN,Yang L,Tang C,et al.Induction of sensitiyity to Doxorubicin and Etoposide by transfection of MCF-7 breast cancer cells with heregulin β-2.Clin Cancer Ras,1998,4(4) :1005-1012. 被引量:1
  • 6Durbecq V,Paesmans M,Cardose F,et al.Topoisomerase- Ⅱ alphaexpression as a predictive marker in a population of advanced breastcancer patients randomly treated either with single-agent doxoru-bicin or single-agent docetaxel.Mol Cancre Ther,2004,3(10): 1207-1214. 被引量:1
  • 7Di LA,Gancberg D,Larsimont D,et al.HER-2 amplification and topoisomerase-Ⅱ alpha gene aberrations as predictive markers innode-positive breast cancer patients randomly treated either withan anthracycline-based therapy or with cyclophosphamide,metho-trexate,and 5-fluorouracil.Clin Cancer Res,2002,8(5): 1107-1116. 被引量:1
  • 8Rahmanzadeh R,Rai P,Celli JP,et al.ki-67 a molecular target for therapy in an in vitro three-dimensional model for o-varian cancer.Cancer Res,2010,70(22): 9234-9242. 被引量:1
  • 9Carey LA,Dees EC,Sawyer L,et al.The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.Clin Cancer Res,2007,15(13): 2329-2334. 被引量:1
  • 10朱学强,任刚,胡洪林.乳腺癌组织中VEGF、C-erbB-2、P53及Ki67的表达与临床意义[J].西部医学,2009,21(3):427-429. 被引量:16

引证文献5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部